The dynamic modulation of optimal total and mutant Ras dosage has been elegantly demonstrated in the characterization of allelic imbalances in mutant versus wild type KRAS during tumor outgrowth and in response to therapy in a mouse model [12]. This evidence concerns the gene KRAS and neoplasm.